⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

September 16, 2024

Supplementary Figure S1 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer

Harshabad Singh Rachel B. Keller Kevin S. Kapner Julien Dilly Srivatsan Raghavan Chen Yuan Elizabeth F. Cohen Michael Tolstorukov Elizabeth Andrews Lauren K. Brais Annacarolina da Silva Kimberly Perez Douglas A. Rubinson Rishi Surana Marios Giannakis Kimmie Ng Thomas E. Clancy Matthew B. Yurgelun Benjamin L. Schlechter Jeffrey W. Clark Geoffrey I. Shapiro Michael H. Rosenthal Jason L. Hornick Valentina Nardi Yvonne Li Hersh Gupta Andrew D. Cherniack Matthew Meyerson James M. Cleary Jonathan A. Nowak Brian M. Wolpin Andrew J. Aguirre

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

KRAS WT pancreatic cancer cohort curation and variant filtering

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Singh et al. (2024) studied this question.

synapsesocial.com/papers/68e5858ab6db6435875229dd https://doi.org/10.1158/1078-0432.27033451.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
2Supplementary Figure S8 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
3Supplementary Figure S8 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
4Supplementary Figure S2 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
5Supplementary Figure S2 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
6Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
7Supplementary Figure S3 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024
8Supplementary Figure S4 from Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer2024